Back to today’s briefing

Story perspectives

Olpasiran Cuts Lipoprotein(a) by 95% in Heart Trial

2/13/2025

39 9

Summary

Story summary

In a groundbreaking Phase II clinical trial, Mount Sinai researchers found that the RNA inhibitor olpasiran slashed lipoprotein(a) levels by more than 95% in patients battling cardiovascular disease, with no significant safety issues reported. Excitingly, a Phase III trial is now in progress to explore olpasiran's promise in heart disease management across the U.S.

1 of 1

Story summary

In a groundbreaking Phase II clinical trial, Mount Sinai researchers found that the RNA inhibitor olpasiran slashed lipoprotein(a) levels by more than 95% in patients battling cardiovascular disease, with no significant safety issues reported. Excitingly, a Phase III trial is now in progress to explore olpasiran's promise in heart disease management across the U.S.